Technical Articles
Immunotherapy
Application of FITC-labeled GUCY2C His-tagged protein in solid tumor immunotherapy research
Guanylyl cyclase C is a transmembrane protein belonging to the receptor guanylyl cyclase family. It is activated by Escherichia coli heat-stable enterotoxin, guanylin, and uroguanylin, transmitting extracellular signals to the intracellular environment and participating in the regulation of intestinal function.
View details
- Cancer
- GUCY2C Protein
- Solid Tumors
- Immunotherapy
Application of Alexa Fluor 647-labeled B7-H3/CD276 Fc chimeric protein in tumor immune-targeted therapy research
B7-H3 is a newly discovered immune checkpoint in recent years, belonging to the B7 superfamily, and is a type I transmembrane glycoprotein. Human B7-H3 possesses four conserved structural cysteines, an extracellular domain composed of IgC-like and IgV-like domains, and distinct intracellular domains.
View details
- Cancer
- B7-H3/CD276
- Tumor Immunity
- Immunotherapy
Application of FITC-labeled Siglec-2/CD22 Fc chimeric protein in B-cell immunotherapy research
CD22, also known as Siglec-2, is a key member of the sialic acid-binding immunoglobulin-like lectin family, belonging to type I transmembrane proteins with a molecular weight of 140 kDa.
View details
- Immunity/Inflamma
- Siglec-2/CD22
- B Cells
- Immunotherapy
Application of PE-labeled MSLN Fc and Avi-tagged proteins in solid tumor immunotherapy research
Mesothelin is a glycosylphosphatidylinositol-anchored cell surface glycoprotein. The MSLN gene is located at 16p13.3 and encodes the MSLN precursor protein, which is proteolytically cleaved to yield two protein products: megakaryocyte potentiating factor and mesothelin.
View details
- Cancer
- MSLN Protein
- Solid Tumors
- Immunotherapy
Application of FITC-labeled GUCY2C Fc chimeric protein in targeted therapy research for colorectal cancer
Guanylyl cyclase C belongs to the receptor guanylyl cyclase family and is the intestinal receptor for bacterial heat-stable enterotoxins, hence it is also known as the heat-stable enterotoxin receptor. The human GUCY2C gene is located on chromosome 12q12, and its encoded product is a type I transmembrane protein with a molecular weight of approximately 120 kDa.
View details
- Cancer
- GUCY2C Protein
- Colorectal Cancer
- Immunotherapy
Application of PE-labeled GUCY2C Fc and Avi-tagged proteins in colorectal cancer immunotherapy research
鸟苷酸环化酶C是一种在人体中由GUCY2C基因编码的酶,属于受体鸟苷酸环化酶家族。该酶是细菌热稳定肠毒素的肠道受体,因此又称为热稳定肠毒素受体。
View details
- Cancer
- GUCY2C Protein
- Colorectal Cancer
- Immunotherapy
Application of Alexa Fluor 647-labeled GPC3 His-tagged protein in liver cancer immunotherapy research
GPC3 is a member of the heparan sulfate proteoglycan family, primarily involved in cell proliferation, differentiation, migration, and apoptosis. This protein is expressed in the liver and kidneys of healthy fetuses but is nearly absent in adult tissues.
View details
- Cancer
- GPC3 Protein
- Liver Cancer
- Immunotherapy
Application of PE-labeled CD19 His-tagged protein in B-cell immunotherapy research
The immune system in the human body has functions such as immune surveillance, immune defense, and immune homeostasis. Its ability to resist the invasion of foreign pathogens and eliminate malignant mutations and senescent cells is primarily achieved through the innate immune system, composed of macrophages and basophils, as well as the adaptive immune system, consisting of T lymphocytes and B lymphocytes.
View details
- Immunity/Inflamma
- CD19
- B Cells
- Immunotherapy
Study on the Role of CD40/CD40L Signaling Pathway in Immunotherapy Based on TR-FRET Technology
CD40 is a member of the tumor necrosis factor receptor superfamily, a 48 kDa type I transmembrane protein widely expressed on immune cells, particularly B cells, dendritic cells, and monocytes, playing a crucial role in bridging innate and adaptive immunity.
View details
- Immunity/Inflamma
- TR-FRET Technology
- CD40/CD40L
- Immunotherapy
Mechanism of IL-21 Protein in Tumor-Targeted Therapy
The lack of functional tumor-infiltrating lymphocytes in the tumor microenvironment is a significant reason for the suboptimal efficacy of tumor immunotherapy. Even in tumor tissues rich in tumor-infiltrating lymphocytes, the presence of dysfunctional PD-1-positive Tim-3-positive CD8-positive T cells remains a major indicator of poor prognosis in cancer patients.
View details
- Cancer
- IL-21 Protein
- Tumor Microenvironment
- Immunotherapy
- 1
- 2






















